Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Uterine Cervical Neoplasms 1Urothelial Cancer 1Small Cell Lung Carcinoma 1Sarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Lung Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Chordoma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Advanced Solid Malignancies 1Advanced Liver Cancers 1

Interventions

Nivolumab 37pembrolizumab 30cabozantinib 27Specimen Handling 25Magnetic Resonance Spectroscopy 22Ipilimumab 20lenvatinib 16Axitinib 15belzutifan 13CTLA-4 Antigen 10Sunitinib 9Biopsy 9Radiosurgery 8atezolizumab 7Immunoglobulin G 5toripalimab 4fludarabine 4avelumab 4aldesleukin 4Everolimus 4Disulfides 4Cyclophosphamide 4zimberelimab 3tivozanib 3spartalizumab 3pazopanib 3palbociclib 3durvalumab 3cemiplimab 3X-Rays 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Tiragolumab × 90 days × Clear all
NCT05805501 2026-05-12

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Hoffmann-La Roche

Phase 2 Active not recruiting
199 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡